Nicotine therapeutic benefits: Difference between revisions

Line 1,705:

='''Tourette's Syndrome'''=

===2019: [https://pmc.ncbi.nlm.nih.gov/articles/PMC6379038/ Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders]===

*Accumulating data from preclinical studies and clinical trials suggest that drugs targeting CNS cholinergic systems may be useful for symptomatic treatment of movement disorders. Nicotinic cholinergic drugs, including nicotine and selective nAChR receptor agonists, reduce L-dopa-induced dyskinesias, as well as antipsychotic-induced tardive dyskinesia, and may be useful in Tourette's syndrome and ataxia. Subtype selective muscarinic cholinergic drugs may also provide effective therapies for Parkinson's disease, dyskinesias and dystonia. Continued studies/trials will help address this important issue.

**Citation: Quik M, Boyd JT, Bordia T, Perez X. Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders. Nicotine Tob Res. 2019 Feb 18;21(3):357-369. doi: 10.1093/ntr/nty063. PMID: 30137517; PMCID: PMC6379038.

***Acknowledgement: This work was supported by grant NS R56NS095965 from the National Institutes of Health.

===2012 [https://pubmed.ncbi.nlm.nih.gov/22776623/ Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond]===

Line 1,712:

Line 1,718:

* [https://sci-hub.se/10.1016/j.physbeh.2012.06.023 PDF Version]

*Citation: Sanberg, P. R., Vindrola-Padros, C., & Shytle, R. D. (2012). Translating laboratory discovery to the clinic: From nicotine and mecamylamine to Tourette’s, depression, and beyond. Physiology & Behavior, 107(5), 801–808. doi:10.1016/j.physbeh.2012.06.023

*Acknowledgement: Paul R. Sanberg and R. Douglas Shytle are inventors on patents related to technology described herein and licensed from the University of South Florida to Targacept, Inc. Because of the historical nature of this article, the authors included a number of self-citations required for a chronological discussion.

===2004 [https://pubmed.ncbi.nlm.nih.gov/15132126/ Clinical and attentional effects of acute nicotine treatment in Tourette's syndrome]===

@@ Line 1,705: / Line 1,705: @@
 ='''Tourette's Syndrome'''=
+===2019: [https://pmc.ncbi.nlm.nih.gov/articles/PMC6379038/ Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders]===
+*Accumulating data from preclinical studies and clinical trials suggest that drugs targeting CNS cholinergic systems may be useful for symptomatic treatment of movement disorders. Nicotinic cholinergic drugs, including nicotine and selective nAChR receptor agonists, reduce L-dopa-induced dyskinesias, as well as antipsychotic-induced tardive dyskinesia, and may be useful in Tourette's syndrome and ataxia. Subtype selective muscarinic cholinergic drugs may also provide effective therapies for Parkinson's disease, dyskinesias and dystonia. Continued studies/trials will help address this important issue.
+**Citation: Quik M, Boyd JT, Bordia T, Perez X. Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders. Nicotine Tob Res. 2019 Feb 18;21(3):357-369. doi: 10.1093/ntr/nty063. PMID: 30137517; PMCID: PMC6379038.
+***Acknowledgement: This work was supported by grant NS R56NS095965 from the National Institutes of Health.
 ===2012 [https://pubmed.ncbi.nlm.nih.gov/22776623/ Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond]===
@@ Line 1,712: / Line 1,718: @@
 * [https://sci-hub.se/10.1016/j.physbeh.2012.06.023 PDF Version]
 *Citation: Sanberg, P. R., Vindrola-Padros, C., & Shytle, R. D. (2012). Translating laboratory discovery to the clinic: From nicotine and mecamylamine to Tourette’s, depression, and beyond. Physiology & Behavior, 107(5), 801–808. doi:10.1016/j.physbeh.2012.06.023
 *Acknowledgement: Paul R. Sanberg and R. Douglas Shytle are inventors on patents related to technology described herein and licensed from the University of South Florida to Targacept, Inc. Because of the historical nature of this article, the authors included a number of self-citations required for a chronological discussion.
 ===2004 [https://pubmed.ncbi.nlm.nih.gov/15132126/ Clinical and attentional effects of acute nicotine treatment in Tourette's syndrome]===